EYE 0.00% 21.0¢ nova eye medical limited

I would personally temper my expectations here a little on near...

  1. 1,695 Posts.
    lightbulb Created with Sketch. 169
    I would personally temper my expectations here a little on near term profitability.

    Do we know which form of profitability that the company is referring to? I prefer NPAT because it is what is available to shareholders. Companies however typically prefer EBITDA because it is easier to generate.

    EBITDA breakeven is possible on a monthly basis towards the end of the calendar year but NPAT breakeven looks like it is futher six months away to me and will require maybe up to $35m of revenue to achieve.

    If I had to guess I would say we are probably looking at a $3-4m NPAT loss in the second half of FY24, versus a $5.6m loss in the first half.

    The good news for the patient is that if/when it becomes apparent that NPAT profitability is guaranteed then I think we can see the big re-rate from 2x sales to 5x sales.
 
watchlist Created with Sketch. Add EYE (ASX) to my watchlist
(20min delay)
Last
21.0¢
Change
0.000(0.00%)
Mkt cap ! $48.10M
Open High Low Value Volume
21.0¢ 21.0¢ 21.0¢ $39.39K 187.5K

Buyers (Bids)

No. Vol. Price($)
1 38328 21.0¢
 

Sellers (Offers)

Price($) Vol. No.
21.5¢ 57167 2
View Market Depth
Last trade - 15.54pm 29/08/2024 (20 minute delay) ?
EYE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.